12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Inecalcitol: Phase II data

Top-line data from a double-blind, French Phase II in 57 evaluable patients with moderate to severe psoriasis showed that once-daily 4 mg oral inecalcitol for 16 weeks missed the primary endpoint of a greater proportion of patients achieving a PASI response vs. placebo. Specifically, 65% of patients receiving inecalcitol (n=37) achieved a PASI 50 response and 27% achieved a PASI 75 response at week 12 or at week...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >